Skip to main content
NBIX
NASDAQ Life Sciences

Neurocrine Q2 Revenue Surges 39% to $959M; Soleno Acquisition Closed, $1B Credit Facility Secured

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$188.65
Mkt Cap
$18.652B
52W Low
$122.138
52W High
$186.12
52W Position info
54% above low
Off High info
at 52W high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

NBIX sits 54% above its 52-week low of $122.138.

Summary

Neurocrine Biosciences reported Q2 2026 revenue of $959M (+39% YoY) and net income of $144.4M, driven by strong product sales and the recent Soleno acquisition. The company also secured a $1B credit facility and continued share repurchases.


Key Events · Earnings and Guidance · NBIX

  • Q2 Revenue Hits $959M

    Total revenues surged 39% year-over-year to $959.0 million, with INGREZZA at $716.5M, CRENESSITY at $183.5M, and newly acquired VYKAT XR contributing $54.3M.

  • Net Income More Than Doubles

    Net income reached $144.4 million, or $1.39 per diluted share, compared to $107.5 million ($1.06) in Q2 2025, driven by revenue growth and a lower effective tax rate.

  • Soleno Acquisition Completed

    The $2.9 billion acquisition of Soleno Therapeutics closed on May 18, 2026, adding VYKAT XR for Prader-Willi syndrome and expanding the rare disease portfolio.

  • $1B Credit Facility Secured

    Entered into a five-year $1.0 billion senior secured revolving credit facility; no borrowings were outstanding as of June 30, 2026, providing significant financial flexibility.


Analysis · NBIX · Life Sciences

A standout quarter saw total revenues jump 39% year-over-year to $959 million, fueled by robust INGREZZA and CRENESSITY sales plus the addition of VYKAT XR from the newly closed Soleno acquisition. Net income more than doubled to $144.4 million, and the company secured a $1 billion revolving credit facility, providing ample liquidity. The period also featured continued share buybacks and the adoption of 10b5-1 trading plans by key executives. The only notable concern is a DOJ civil investigative demand regarding INGREZZA marketing practices, though the company is cooperating.

At the time of this filing, NBIX was trading at $188.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7B. The 52-week trading range was $122.14 to $186.12. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NBIX - Latest Insights

NBIX
Jul 30, 2026, 4:12 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $185.50
Real-time Price: $188.65 info
Change: +$3.15 (+2%) info
Market Cap: $18.652B info
NBIX
Jul 30, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $190.75
Real-time Price: $188.65 info
Change: -$2.10 (-1%) info
Market Cap: $18.652B info
NBIX
May 28, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $156.39
Real-time Price: $188.65 info
Change: +$32.26 (+21%) info
Market Cap: $18.652B info
NBIX
May 19, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $157.21
Real-time Price: $188.65 info
Change: +$31.44 (+20%) info
Market Cap: $18.652B info
NBIX
May 18, 2026, 9:04 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $158.42
Real-time Price: $188.65 info
Change: +$30.23 (+19%) info
Market Cap: $18.652B info